Jessica Meidinger
Associate Director, Analytical Development at QED Therapeutics - Palo Alto, CA, US
Jessica Meidinger's Colleagues at QED Therapeutics
Jessica Meidinger's Contact Details
HQ
650-231-4088
650-231-4088
Location
Company
QED Therapeutics
QED Therapeutics
Jessica Meidinger's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Jessica Meidinger
Jessica Meidinger currently works for QED Therapeutics.
Jessica Meidinger's role at QED Therapeutics is Associate Director, Analytical Development.
Jessica Meidinger's email address is ***@qedtx.com. To view Jessica Meidinger's full email address, please signup to ConnectPlex.
Jessica Meidinger works in the Biotechnology industry.
Jessica Meidinger's colleagues at QED Therapeutics are Miki Yamamoto, Scott Collins, Dawn Hill, Mike Monteith, Stacie Shepherd, Todd Bobick, Mar Reyes and others.
Jessica Meidinger's phone number is 650-231-4088